Latest Breaking News On - கிரெகொரி கெலீ - Page 6 : comparemela.com

Share: CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) Foghorn Therapeutics Inc. (NASDAQ:FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Sam Agresta, M.D., M.P.H, Chief Medical officer is scheduled to participate in a Leukemias panel discussion at the Cowen 41 st Annual Healthcare Conference at 11:40 a.m. ET on March 3, 2021. About Foghorn Therapeutics Foghorn ® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control ® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

United kingdomFanny cavaliSam agrestaGregory kelleyFoghorn therapeutics incChief medicalAnnual healthcare conferenceGene trafficஒன்றுபட்டது கிஂக்டம்கிரெகொரி கெலீஃபாக்ஹோர்ந் சிகிச்சை இன்க்தலைமை மருத்துவஆண்டு சுகாதாரம் மாநாடுகீந் போக்குவரத்து